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Abstract
Purpose Translocator protein (TSPO) is a biomarker of
neuroinflammation that can be imaged by PET using
[11C]-(R)PK11195. We sought to characterize the
[11C]-(R)PK11195 kinetics in gliomas of different histotypes
and grades, and to compare two reference tissue input func-
tions (supervised cluster analysis versus cerebellar grey
matter) for the estimation of [11C]-(R)PK11195 binding in
gliomas and surrounding brain structures.
Methods Twenty-three glioma patients and ten age-matched
controls underwent structural MRI and dynamic
[11C]-(R)PK11195 PET scans. Tissue time–activity curves
(TACs) were extracted from tumour regions as well as grey
matter (GM) and white matter (WM) of the brains.
Parametric maps of binding potential (BPND) were gen-
erated with the simplified reference tissue model using
the two input functions, and were compared with each
other. TSPO expression was assessed in tumour tissue
sections by immunohistochemistry.
Results Three types of regional kinetics were observed in
individual tumour TACs: GM-like kinetics (n=6, clearance
of the tracer similar to that in cerebellar GM), WM-like
kinetics (n=8, clearance of the tracer similar to that in cerebral
WM) and a form of mixed kinetics (n=9, intermediate rate of
clearance). Such kinetic patterns differed between low-grade
astrocytomas (WM-like kinetics) and oligodendrogliomas
(GM-like and mixed kinetics), but were independent of tu-
mour grade. There was good agreement between parametric
maps of BPND derived from the two input functions in all
controls and 10 of 23 glioma patients. In 13 of the 23 patients,
BPND values derived from the supervised cluster input were
systematically smaller than those using the cerebellar input.
Immunohistochemistry confirmed that TSPO expression in-
creased with tumour grade.
Conclusion The three types of [11C]-(R)PK11195 kinetics in
gliomas are determined in part by tracer delivery, and indi-
cated that kinetic analysis is a valuable tool in the study of
gliomas with the potential for in vivo discrimination be-
tween low-grade astrocytomas and oligodendrogliomas.
Supervised cluster and cerebellar input functions produced
consistent BPND estimates in approximately half of the
gliomas investigated, but had a systematic difference in the
remainder. The cerebellar input is preferred based on theo-
retical and practical considerations.
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Introduction
Translocator protein (TSPO), formerly known as peripheral
benzodiazepine receptor, is an 18-kDa mitochondrial mem-
brane protein mainly expressed in cells of the mononuclear
phagocyte lineage [1, 2]. In the normal central nervous
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system, TSPO expression is low and limited to vessels,
perivascular macrophages and ependyma [3, 4]. In contrast,
its expression increases considerably in microglia/macrophages
in pathological conditions when any insult to brain tissue has
occurred [5]. For this reason, TSPO is regarded as a reliable
biomarker of neuroinflammation for the detection of active
pathological processes [1].
[11C]-(R)PK11195 is a highly selective radioligand for
TSPO [6] and has been used extensively with PET for in vivo
visualization of microglial activation in acute and chronic
inflammatory as well as noninflammatory brain disorders
[3, 7–13]. [11C]-(R)PK11195-specific binding is minimal in
normal brain but increases significantly in areas of
neuroinflammation. Different methods of kinetic modelling
for quantification of [11C]-(R)PK11195 binding have been
assessed. Kropholler et al. [14, 15] recommended a reversible
two-tissue compartment model with K1/k2 fixed to the whole
cortex when a metabolite-corrected arterial plasma input func-
tion is available, whilst the simplified reference tissue model
(SRTM [16]) is considered the best alternative in the absence
of an arterial input function. Schuitemaker et al. [17] found that
the basis function implementation of SRTM [18] performed
the best amongst reference tissue techniques for generating
parametric images of [11C]-(R)PK11195 binding potential.
Given the expression of TSPO in endothelial cells and smooth
muscle, a modified SRTM with blood volume term was sub-
sequently developed to account for differences in vascular
binding, not only between reference and target regions but also
amongst study cohorts [19].
The SRTM does not require a plasma input function, and
therefore there is no need for arterial cannulation. It aims to
provide a measure of specific binding. However, the model
relies on the assumptions that: (1) a reference region devoid of
specific binding exists, and (2) the nonspecific binding is the
same in both the reference and target regions. Some studies
have adopted the cerebellum as a standard reference tissue [2,
10, 20–22], although it has been argued that the cerebellum
may be inappropriate due to the possible presence of activated
microglia in certain brain disorders [15, 23], and the presence
of TSPO in vessels which cannot be resolved with the spatial
resolution of clinical PET scanners. Cluster analysis, a ‘data-
driven’ approach, was introduced as an alternative for the
extraction of normal tracer kinetics to serve as a reference
region input function and was adopted for [11C]-(R)PK11195
studies [7, 24, 25] in the form of unsupervised cluster analysis.
In order to extract as reference tissue a cluster of grey matter
voxels devoid of both specific binding and spurious signals
(particularly from the blood pool and muscle), Turkheimer et
al. [4] then developed a supervised clustering approach using
six predefined kinetic classes, that is for normal grey matter
(GM), white matter (WM), skull, muscle, blood pool and
pathological TSPO binding. This technique combined with
SRTM has been shown to produce highly reproducible and
reliable estimates of [11C]-(R)PK11195 binding in healthy
volunteers and patients with Huntington’s disease [4].
Furthermore, a modified supervised cluster algorithm has
been proposed, focusing on brain tissue with only four kinetic
classes (previous skull and muscle classes omitted) to improve
its performance [26]. Nonetheless, developments in kinetic
methodology are still ongoing with the aim of validating the
appropriate plasma and reference region compartmental
models for organs and pathologies that have not yet been
studied.
TSPO expression has also been investigated in gliomas.
Pathological studies on surgical samples of astrocytoma have
demonstrated that TSPO is expressed predominantly in neo-
plastic cells and it is higher in WHO grade III and IV lesions
[27, 28]. In contrast, there are no published data on TSPO
expression in oligodendrogliomas. Only three PET studies
using [11C]-PK11195 have so far been performed [29–31] in
a small number of patients with astrocytoma. These studies
have shown conflicting results, suggesting either increased or
decreased [11C]-PK11195 uptake in the tumours. Different
kinetic modelling approaches in these studies might have
accounted for the inconsistent findings, and detailed charac-
terization of tracer behaviour within the tumours is not avail-
able, particularly for low-grade gliomas (LGG).
In the present study, we therefore examined patients with
LGG or high-grade gliomas (HGG) of different subtypes
(mainly astrocytoma and oligodendroglioma) to investigate
systematically [11C]-(R)PK11195 kinetics in the tumours, using
the SRTM comparing supervised clustered GM and cerebellar
GM as reference tissue input functions. Our hypothesis was that
different histotypes and grades of gliomas could be discrimi-
nated by differences in [11C]-(R)PK11195 kinetics. Such dis-
crimination is still a challenge with conventional contrast CT
andMR imaging in clinical practice. Therefore, we investigated
whether [11C]-(R)PK11195 tracer kinetic analysis can provide
this information, and which reference tissue input function is
more suitable for glioma studies.
Materials and methods
Patients and control subjects
The study group recruited comprised 23 patients (mean age
40 years, age range 22 – 73 years; 16 men, 7 women) with
histologically proven glioma (clinical information is provid-
ed in Tables 1 and 2). None of the patients had concurrent
systemic disease, and none of them had had surgical inter-
vention, radiotherapy or chemotherapy prior to PET scan-
ning. None of the patients were taking benzodiazepines.
Nine patients were taking dexamethasone. In seven of these
patients it was stopped for at least 2 weeks prior to the PET
scan because of its potential suppressive effect on microglial
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activation [32–34], but in two (patients 16 and 20) discon-
tinuation was considered clinically contraindicated. Ten
healthy volunteers (mean age 44 years, age range
23 – 68 years; 7 men, 3 women) were also scanned.
Their past medical history was unremarkable; they all
had normal physical and neurological examinations and
showed no significant structural lesions on anatomical
MRI as judged by an experienced neuroradiologist
(A.J.).
Written informed consent was obtained from all partici-
pants. This study was approved by the Wrightington, Wigan
and Leigh Ethics Committee as well as the University of
Manchester Ethics Committee. Permission to administer ra-
dioisotopes was granted by the Administration of Radioactive
Substances Advisory Committee of the Department of Health
(ARSAC), UK.
Volumetric MRI
All subjects underwent a structural MRI scan within 1 month
before the PET procedure. High-resolution 3-D T1-weighted
spoiled gradient recalled echo and inversion recovery (IR)
sequences were acquired on a 3-T (patients) or a 1.5-T
(controls) scanner (Philips Achieva; Philips Medical
Systems, Best, The Netherlands). The protocol for patients
also included standard anatomical imaging, i.e. T2-weighted
and fluid-attenuated inversion recovery (FLAIR) sequences,
and gadolinium (Gd) contrast-enhanced images.
[11C]-(R)PK11195 production and PET acquisition
[11C]-(R)PK11195 (1-(2-chlorophenyl)-N-methyl-N-(1-
methylpropyl)-3-isoquinoline carboxamide) was synthesized













1 41 M O II Frontal-temporal lobe (right) No Mixed ++ ++
2 25 F A II Frontal lobe (right) No WM-like ++ ++
4 45 M O II Medial temporal lobe (right) No Mixed Not enough tissue
5 24 F OA II Parietal lobe (right) No WM-like ++ ++
6 40 M O II Frontal lobe (right) No GM-like + ++
7 73 F Not operated LGG Thalamus (left) No Mixed No tissue
8 63 F A II Parietal, frontal, temporal lobe (left) No GM-like ++ ++
9 33 M A II Posterior frontal lobe (right) No WM-like ++ ++
11 30 M O II Posterior frontal lobe (right) No Mixed ++ ++
12 47 F A II Temporal lobe (left) No WM-like ++ ++
17 33 M A II Frontal lobe (left) No WM-like ++ ++
18 42 M OA II Temporal lobe (left) No Mixed ++ ++
20 24 M O II Frontal-temporal lobe (right) No Mixed + ++
22 50 F O II Frontal lobe (left) No GM-like ++ +++
A astrocytoma, O oligodendroglioma, OA oligoastrocytoma











3 37 M AA III Frontal-temporal lobe (right) None WM-like ++ ++
10 42 M AA III Posterior frontal lobe (left) Focal Mixed ++ ++
13 46 M AA III Parietal lobe (left) Focal Mixed ++ ++
14 57 M GBM IV Posterior frontal lobe (left) Focal Mixed +++ +++
15 22 M A OA III Frontal-parietal lobe (right) Minor GM-like ++ ++
16 41 M GBM IV Temporal-occipital lobe (right) Massive WM-like (high) +++ +++
19 52 M AA III Parietal lobe (left) Minor GM-like +++ +++
21 40 F GBM IV Frontal lobe (right) Massive WM-like (high) +++ +++
23 24 M AO III Frontal-temporal lobe (left) Minor GM-like ++ ++
AA anaplastic astrocytoma, AO anaplastic oligodendroglioma, A OA anaplastic oligoastrocytoma, GBM glioblastoma
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as described previously [6, 35]. All PET scans were performed
on a high-resolution research tomograph (HRRT; Siemens/CTI,
Knoxville, TN). The axial and transaxial fields of view of this
3-D dedicated brain scanner were 25 cm and 35 cm, respec-
tively, giving an intrinsic spatial resolution of approximately
2.5 mm. A 7-min transmission scan using a 137Cs point source
was acquired for subsequent attenuation and scatter correction.
Shortly after the start of the emission scan, [11C]-(R)PK11195
was injected intravenously as a slow bolus over approximately
15 s. The administration parameters in patients and controls are
given in Table 3. Emission data were then acquired over 60min
in list mode as 18 time-frames (one background frame of
approximately 7 min prior to injection, followed by 17 frames:
1×15 s, 1×5 s, 1×10 s, 1×30 s, 4×60 s, 7×300 s and 2×
600 s). The subject’s head position was indicated (using laser
beams) and monitored (via a camera) throughout the scan and
corrected immediately if necessary.
Image reconstruction and analysis
The multiframe PET images were reconstructed with the itera-
tive ordinary Poisson ordered-subset expectation maximization
(OP OSEM) 3-D algorithm, incorporating normalization and
corrections for random coincidences, scattered radiation and
attenuation [36]. For reconstruction 16 subsets were used, and
the reconstructionwas run for 12 iterations for themean activity
concentration value at the volume-of-interest level to converge.
The voxel size of the reconstructed PET images was 1.22×
1.22×1.22 mm3. After reconstruction, images were regularized
with a 3-D gaussian filter of 4 mm full-width at half-maximum
to reduce image noise at the voxel level prior to calculation of
parametric maps with the SRTM [37].
Individual MRI scans were coregistered with the summed
PET images [38], and the T1-weighted IR images were seg-
mented into GM and WM probability maps [39]. The inverse
transformation parameters from segmentation were used to
warp a maximum probability brain atlas [40, 41] into individ-
ual space. The quality of the coregistration, segmentation and
normalization was visually inspected for accurate anatomical
colocalization. On observation, the warped brain atlas was
distorted regionally in the tumours and their margin as expected,
but matched the extratumoral structures well, especially in the
cerebral hemisphere contralateral to the tumour and in the cere-
bellum. Any mismatch in extratumoral structures was corrected
manually. Then the GM probability map was binarized using a
0.5 threshold and applied as a mask to the brain atlas, from
which an individualizedGMatlas was created. Both atlaseswere
used to sample the ratio of influx (RI, representing the ratio of
tracer delivery to the target region to delivery to the reference
region) and binding potential (BPND, representing the ratio of
specifically bound radioligands to nondisplaceable ones in tissue
at equilibrium [16, 42]) values from parametric images. Given
the unpredictable spatial distribution of activated microglia in
disease, the pixel-by-pixel generation of parametric images was
preferred over the calculation of binding parameters from time–
activity curves (TACs) extracted from anatomical regions of
interest (ROIs) in our study [43].
For practical reasons, no arterial input function was
obtained (unavailability of reliable analysis for radiolabelled
metabolites of [11C]-(R)PK11195 at the time of study setup,
and potential reduction in recruitment of patients with HGG
whose time window for participation prior to surgical inter-
ventions was short). Two different reference input functions
were used: (1) a cluster of GM voxels extracted from the
supervised clustering algorithm [4], and (2) total GM of the
bilateral cerebellum, as it is a large and relatively homoge-
neous structure distant from the tumours [44, 45]. The BPND
parametric images obtained using different reference tissue
input functions were compared with each other.
Each tumour (including visible oedema, if present) was
manually delineated on the coregistered T2-weighted FLAIR
MR image and confirmed against the T1-weighted contrast-
enhanced MR image. A region of WM was also drawn in the
contralateral centrum semiovale. These ROIs, together with the
individualized GM atlas, were projected onto parametric im-
ages and dynamic PET volumes to extract group mean RI and
BPND values as well as TACs from the tumours, centrum
semiovale WM and cerebellar GM. Individual tumour TACs
were compared with corresponding GM and WM TACs, from
which radioactivity ratios of tumour to GM (tumour/GM) and
tumour to WM (tumour/WM) were obtained for each temporal
frame. Then the time-courses of tumour/GM and tumour/WM
ratios from radioactivity peak to scan end were outlined for
each scan, and mean tumour/GM and tumour/WM ratios were
calculated by weighting the ratios against the frame lengths.
Group means (average of the mean ratios of all scans) and
standard deviations (SD) were also derived.
Pathological assessments
The extent of TSPO expression and microglial/macrophagic
infiltrate was characterized semiquantitatively on the
tissue sections of 21 tumours using immunoperoxidase
Table 3 Age and [11C]-(R)PK11195 administration parameters (means ±






Age (years) 40±13 44±15
Injected dose (MBq) 517±127 549±124
Specific activity (GBq/μmol) 130±48 111±56
Injected mass of stable
PK11195 (μg)
1.6±0.8 2.4±2.1
Radiochemical purity (%) 98.4±0.9 98.3±0.9
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immunohistochemistry with antibodies against TSPO (goat
polyclonal, GeneTex; dilution 1:750) and Iba1 (rabbit poly-
clonal, WAKO/019-19741; dilution 1:500), respectively. In
patient 4, the tissue left after routine neuropathological assess-
ments was too small for immunostaining.
TSPO-positive and TSPO-negative neoplastic cells were
identified by their nuclear morphology (hyperchromatic nu-
cleus). We assigned a score of 3+ to lesions showing more
than 25 % TSPO-positive tumour cells, a score of 2+ to those
showing expression between 5 and 25 % and a score 1+ to
those showing only scattered positive cells (less than 5 %).
Perivascular macrophages and endothelial cells in the tissue
adjacent to the tumour were considered as positive control.
Neoplastic cells showed different staining intensities, but this
parameter was difficult to assess semiquantitatively.
Haemorrhagic areas, microcysts and necrosis as well as the
fields at the edge of tissue sections were avoided.
A similar method was used to assess the number of mi-
croglia identified with the immunostaining for Iba1, a
calcium-dependent molecule that is a widely recognized
marker of macrophages and microglia and is known to be
expressed in ramified, quiescent to fully activated microglia
[46]. Only a few microglia expressed TSPO but an accurate
estimate of TSPO-positive microglia could not be achieved
using immunoperoxidase immunohistochemistry.
Statistical analysis
All data are expressed as means ± SD. [11C]-(R)PK11195
uptake parameters in different kinetics were compared using
the Kruskal-Wallis test with post hoc tests. BPND parametric
images generated using different input functions were com-
pared pixel-by-pixel using Bland-Altman plots [47] with
local regression [48]. Regional BPND values derived from
the two input functions were compared using a general
linear model (GLM, repeated measures) with input function
and region as within-subjects variables. A probability value
of p<0.05 was considered statistically significant.
Results
Tracer kinetic analysis
Injection of [11C]-(R)PK11195 resulted in a rapid initial
peak of activity in the TACs. After this peak, the TACs of
cerebellar GM (Fig. 1a, red lines) exhibited a sharp decline
in radioactivity over the first 3 min, followed by a gradual
decrease to the end of scanning, falling to, or below, the
level of the WM TACs during the last 25 min. Similar initial
peaks (reaching 45 – 73 % of the level of cerebellar GM)
and fast washout in the next 3 – 5 min were also seen in the
TACs of the contralateral centrum semiovale WM (Fig. 1a,
amber lines). Subsequently the amount of radioactivity
reached a plateau and stayed at this low background level
throughout the scan, indicating slow clearance of the tracer.
The TACs of normal GM and WM in patients appeared
similar to those in healthy volunteers.
In gliomas, the initial tracer uptake peaked at least to the
level of that inWM in all patients, despite variable amounts of
radioactivity in the tumour regions across subjects. Three
types of regional kinetics were found in individual tumour
TACs (Fig. 1): GM-like kinetics (n=6, tracer clearance similar
to that in the cerebellar GM; group mean tumour/GM ratios
1.12±0.08 and tumour/WM ratios 1.39±0.14), WM-like ki-
netics (n=8, tracer clearance similar to that in the WM, with a
slight descent after the plateau at the midway time points, i.e.
30 – 40 min; group mean tumour/GM ratios 0.81±0.29 and
tumour/WM ratios 0.97±0.31), and mixed kinetics (n=9,
intermediate rate of clearance; group mean tumour/GM ratios
0.92±0.11 and tumour/WM ratios 1.10±0.16). In addition to
the typical examples illustrated in Fig. 1, variable levels of
[11C]-(R)PK11195 uptake within the tumours led to a few
atypical TAC shapes in the WM-like kinetic type, where two
glioblastomas (GBMs) with massive Gd enhancement in the
contrast MR images displayed WM-like kinetics at a level
approximately 0.5-fold higher than the WM throughout the
acquisition (Fig. 2). Kinetic classification of such cases relied
more on visual inspection of the TACs rather than on calcu-
lation of mean tumour/GM and tumour/WM ratios. In general,
the three types of tracer kinetics were independent of
glioma grades, but appeared to differ between different
histological subtypes in tumours without Gd enhancement on
MRI indicating an intact blood–brain barrier (BBB).
Four of five low-grade astrocytomas displayed WM-like trac-
er kinetics within the tumours, whilst the six low-grade
oligodendrogliomas demonstrated mixed or GM-like kinetics
(Tables 1 and 2).
RI values of whole tumour ROIs were calculated using
either cerebellar GM or the supervised cluster of GM as





super were separated evenly into three
categories (high, moderate and low) based on the range of
values and linked to the three types of tumour kinetics (Fig. 3).
With the cerebellar input function, all four tumours (100 %)
with high RI
cerebellum showed GM-like TACs. six of seven
tumours (86 %) with low RI
cerebellum showed WM-like TACs
and the remaining one showed a mixed TAC. Of 12 tumours
with moderate RI
cerebellum, eight (67 %) showed mixed TACs,
whereas two showed GM-like TACs and two showed WM-
like TACs. With the supervised cluster input function, five of
seven tumours (71 %) with high RI
super showed GM-like
TACs and the remaining two showed mixed TACs. All four
tumours (100 %) with low RI
super showed WM-like TACs.
Of 12 tumours with moderate RI
super, seven (58 %)
showed mixed TACs, whereas one showed a GM-like TAC
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and four showed WM-like TACs. The Kruskal-Wallis test
showed a significant effect of TAC grouping on both
RI
cerebellum and RI
super estimates (p=0.003 and 0.001, respec-
tively), where the mean RI
cerebellum or RI
super of each TAC type
differed (all p<0.05).
Albeit closely correlated (r=0.95, p<0.0001), tumour
RI
super was generally lower than tumour RI
cerebellum, indicat-
ing certain differences in the two reference regions. The
influence of different reference regions on BPND estimates
was investigated as discussed in the following sections.
Supervised cluster analysis versus cerebellum as reference
Healthy volunteers
Pixel-by-pixel comparisons of BPND parametric maps de-
rived from supervised cluster analysis (BPND
super) and cer-
ebellar GM (BPND
cerebellum) as input function are shown in
Fig. 4. In Bland-Altman plots the majority of the points
clustered closely around zero, with a generally horizontal
line of local regression in each case (Fig. 4b). This finding is
in keeping with the observation that TACs of the two refer-
ence regions mostly overlap (Fig. 4c), thus resulting in
similar BPND estimates, despite the difference during the
first 20 min. The first peak in both TACs reflected the initial
peak from the vascular signals, while the second peak in the
TACs of the supervised cluster represented tracer reperfu-
sion and uptake in the tissue (Fig. 4c). BPND
super and
BPND
cerebellum values were sampled from 12 ROIs (temporal
lobe, frontal lobe, occipital lobe, parietal lobe, thalamus and
putamen in the left and right hemispheres). GLM analysis
revealed neither an effect of input function on BPND (F=
0.027, p=0.874) nor any cross effects between the input
function and region or side, indicating that BPND
super did
not differ from BPND
cerebellum across all ROIs in the control
subjects.
Fig. 1 a Representative tumour TACs of the three kinetic types from
three example scans. Radioactivity concentration was plotted against
frame midpoints. b Time-course (from the initial peak to scan end) of
the tumour/GM (cerebellum) and the tumour/WM (centrum semiovale)
ratios of the three kinetic types, plotted as means ± SD




cerebellum values were sampled from eight
ROIs (tumour, ipsilateral cerebral hemisphere excluding the
tumour region, and temporal lobe, frontal lobe, occipital lobe,
parietal lobe, thalamus and putamen in the contralateral hemi-
sphere). GLM analysis showed a significant effect of input
function on BPND estimates (F=16.94, p=0.0005) and a cross
effect between the input function and region (F=2.69, p=
0.048). Subsequently, parametric maps of BPND
super and
BPND
cerebellum were compared pixel-by-pixel in each individual
to identify subjects in whom the two input functions differed.
A similar pattern in the Bland-Altman plots was found in
10 out of 23 glioma patients (44 %), in both the tumour
regions and tumour-free regions of the brain (Fig. 5), indi-
cating good agreement between the BPND parametric maps
derived from the two input functions. GLM analysis in this
subgroup showed neither an effect of input function (F=
2.05, p=0.186) nor a cross effect between the input function
and region.
In 13 of 23 patients (56 %), the Bland-Altman plots and
local regression analyses revealed consistently smaller, but
correlated, BPND
super than BPND
cerebellum values, again both
inside and outside the tumours in the brain (Fig. 6). This
finding is in keeping with the observation that TACs of the
supervised cluster of GM remained slightly higher than those
of the cerebellar GM throughout the acquisition (Fig. 6c), thus
producing smaller BPND estimates. GLM analysis in this
subgroup confirmed a significant effect of input function on
BPND (F=96.46, p<0.0001) and a cross effect between the
input function and region (F=4.88, p=0.036), indicating that
BPND
super differed fromBPND
cerebellum across all ROIs in 56%
of our glioma patients.
The locations of significant binding were independent of
the input function used. They remained identical in the two
BPND maps of the same patient or control subject.
Fig. 2 a Tumour TACs of two GBMs (with massive Gd enhancement
in the contrast MRI) that displayed WM-like kinetics at a high level of
radioactivity concentration (approximately 0.5-fold higher than that in
WM), plotted against frame midpoints. b Corresponding time-course
(from the initial peak to scan end) of tumour/GM (cerebellum) and
tumour/WM (centrum semiovale) ratios in the two patients
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Neuropathology
The number of TSPO-positive neoplastic cells increased
with tumour grade (Fig. 7) and the number was higher in
GBMs. The results of the semiquantitative analysis are
summarized in Tables 1 and 2. In addition, high-grade
lesions demonstrated more intense immunolabelling
(Fig. 7c). The number of microglia increased with tumour
grade, but only a minority of them appeared to express
TSPO. The majority of normal, preexisting vessels in low-
grade astrocytomas and low-grade oligodendrogliomas
showed TSPO-positive endothelial cells, although some
degree of variability was observed between different regions
of the same tumour and between different subjects.
Interestingly, newly formed vessels and proliferative endo-
thelium in GBMs conversely showed consistently low to
negative TSPO.
Discussion
Understanding the different tumour TACs
One major finding of this study is the three types of tracer
kinetics in gliomas, and the different kinetics between low-
grade astrocytomas (WM-like TAC) and low-grade
oligodendrogliomas (GM-like and mixed TACs). This differ-
ence is of clinical interest because the distinction between
these two glioma subtypes is important but currently difficult
on conventional neuroimaging. Such early distinction is valu-
able in therapeutic stratification and outcome prediction since
oligodendrogliomas show better responses to chemotherapy
and significantly improved overall survival than astrocytomas
of a comparable grade [49].
There are several possible reasons for the different
kinetics between low-grade astrocytomas and low-grade
Fig. 3 Relationship among the three categories of tumour RI (calculated with cerebellar input or supervised cluster input) and the three types of
tumour TACs
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oligodendrogliomas. TSPO is known to form homopolymers,
predominantly dimers and trimers, that seem to increase during
cell proliferation and to complex with other mitochondrial
proteins present in the outer and inner mitochondrial membrane
as part of the mitochondrial permeability transition pore. In
addition, the TSPO functions seem to be affected by tissue-
specific and cell-specific proteins as well as the lipid composi-
tions of the mitochondrial membranes [50]. Formation of dif-
ferent homopolymers or heteropolymers or differences in
protein and lipid composition may be responsible for the dif-
ferent kinetics between astrocytomas and oligodendrogliomas.
Although our histology results did not show obvious difference
in endothelial TSPO between the two histotypes, increased
vascularity in oligodendrogliomas [51] may also explain the
kinetic behaviour similar to that in the GM in these tumours.
Our results showed predominantly TSPO expression in neo-
plastic cells in both histotypes of glioma, which is in keeping
with the findings of previous pathological studies on astrocytic
tumours [27, 28], and suggests that microglia/macrophages do
not interfere with [11C]-(R)PK11195 uptake in gliomas. Hence,
the difference in kinetics between low-grade astrocyto-
mas and oligodendrogliomas is less likely to be caused
by different cellular sources of TSPO expression. A recent
PET study on two anaplastic astrocytomas also indicated that
glioma-infiltrating microglia fail to express TSPO [31].
Nevertheless, further work is needed to investigate TSPO in
oligodendrogliomas and the contribution of reactive astro-
cytes, endothelia and microglia to [11C]-(R)PK11195 binding.
In one low-grade astrocytoma with exceptional GM-like
kinetics (patient 8), the tumour grade might have been
underestimated. This 63-year-old patient underwent biopsy
rather than surgical debulking, and the limited amount of
tissue obtained might not have been representative of the
grade. The patient showed clinical and radiological progres-
sion 6 months after the biopsy, a behaviour that is more in
keeping with a HGG.
Eight HGGs with varying degrees of Gd enhancement
(three slightly enhanced, three focally enhanced and two mas-
sively enhanced) were characterized by GM-like, mixed and
WM-like kinetics, respectively (Table 2). This observation
suggests a direct relationship between BBB status and tracer
kinetic behaviour in these tumours. In the three patients with a
mildly disturbed or relatively intact BBB, [11C]-(R)PK11195
accumulated in both the normal brain and tumour tissue rap-
idly, followed by a slightly slower washout from tumour tissue
than from the GM.We believe that this subtle retention reflects
binding in the tumours. In the two patients with a significantly
damaged BBB, the tracer also accumulated in the tumours
Fig. 4 Parametric maps of BPND
super and BPND
cerebellum in a represen-
tative control subject (65-year-old man). a Parametric maps of
BPND
super and BPND
cerebellum superimposed on T1-weighted MR im-
ages; the colour bar indicates BPND values. b Pixel-by-pixel Bland-
Altman plot comparing the values from the two parametric maps. Each
black dot is derived from a pixel in the brain and the red dashed line
denotes local regression. c Corresponding individual TACs of the
supervised cluster of GM (red) and cerebellar GM (black)
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quickly, but the washout from tumour tissue was much slower
and stayed at a level higher than that in GM from 15 min after
injection (Fig. 2). This retention reflected considerable
[11C]-(R)PK11195 binding to the TSPO highly expressed by
neoplastic cells and possibly macrophages infiltrated from the
bloodstream. In the three patients with focal Gd enhancement
indicating regional disruption of the BBB, the tracer behaved
in a mixed fashion in-between GM-like andWM-like kinetics.
It can be argued that different degrees ofWM-like kinetics may
be a characteristic of BBB leakage and subsequent
[11C]-(R)PK11195 accumulation and elevated binding in these
eight HGGs. However, since all three types of tumour TAC
were detected in the nonenhancing gliomas, the impact of BBB
leakage in determining the profiles of tracer uptake kinetics is
limited. Other mechanisms such as tracer delivery and tumour
heterogeneity may be more relevant.
[11C]-(R)PK11195 is highly lipophilic and it can cross the
intact BBB by passive diffusion. Its delivery is not predomi-
nantly determined by BBB leakage. This is supported by our
tumour RI data (both RI
cerebellum and RI
super; Fig. 3) where
tumours with massive or focal Gd enhancement demonstrated
only moderate RI. Therefore, the influence of tumour RI on
tracer kinetics was investigated. The three categories of
tumour RI, especially the high and low categories, generally
matched the three types of tumour uptake kinetics. This,
together with the TAC grouping effect on RI, suggests that
tracer delivery contributes in part to their kinetic behaviour
within the tumours. Such an interpretation can be derived
from either the RI
cerebellum or the RI
super data, although the
distribution of patients in the RI categories varied depending
on the reference region used, which was caused by the
different ranges of RI
cerebellum and RI
super values. In addition,
kinetic analysis revealed that the initial accumulation of
[11C]-(R)PK11195 peaked at least to the level of the WM in
all tumour TACs, indicating sufficient delivery of the radio-
tracer into the tumours. Subsequent binding was not hampered
by the relatively low tumour RI in some patients in whom
blood flow and/or tracer extraction in tumour regions may be
less than that in the reference GM. Moreover, the inhomoge-
neous tracer kinetics across these tumours mirrors the hetero-
geneous nature of gliomas, and also reflects the fact that
tumour uptake kinetic behaviour is mostly in the range be-
tween normal GM and WM. Overall, [11C]-(R)PK11195
proved to be a suitable radiotracer for glioma investigation,
because it can be delivered sufficiently into the tumour, was
not dependent on BBB leakage, and was taken up by the
Fig. 5 Parametric maps of BPND
super and BPND
cerebellum in a represen-
tative glioma patient (patient 10). a Parametric maps of BPND
super and
BPND
cerebellum superimposed on T1-weighted MR images. Note the
high BPND area within the tumour (arrows BPND
super=0.52±0.14,
BPND
cerebellum=0.52±0.14); the colour bar indicates BPND values. b
Pixel-by-pixel Bland-Altman plot comparing the values from the two
parametric maps. Each black dot is derived from a pixel in the brain,
and each blue dot from a pixel in the tumour; the red dashed line and
purple solid line denote local regression in the brain pixels and tumour
pixels, respectively. c Corresponding individual TACs of the super-
vised cluster of GM (red) and cerebellar GM (black)
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tumour within the framework of known kinetics. Finally,
given the inhomogeneous uptake behaviour amongst gliomas,
we stress that visual inspection of tumour TACs from dynamic
scanning is as informative as quantification of tumour/GM
and tumour/WM ratios in kinetic analysis, especially with
regard to atypical cases.
Fig. 6 Parametric maps of BPND
super and BPND
cerebellum in a represen-
tative glioma patient (patient 4, the patient showing the maximal
differences). a Parametric maps of BPND
super and BPND
cerebellum
superimposed on T1-weighted MR images. Note the high BPND area
within the tumour (arrows BPND
super=0.25±0.09, BPND
cerebellum=0.52±
0.11); the colour bar indicates BPND values. b Pixel-by-pixel Bland-
Altman plot comparing values from the two parametric maps. Each black
dot is derived from a pixel in the brain, and each blue dot from a pixel in
the tumour; the red dashed line and purple solid line denote local
regression in the brain pixels and tumour pixels, respectively. c Corre-
sponding individual TACs of the supervised cluster of GM (red) and
cerebellar GM (black)
Fig. 7 TSPO expression in relation to tumour grade. a Patient 20 with
low-grade oligodendroglioma, quantified as +: expression is limited to
a few neoplastic cells; endothelial cells are positive (arrows). b Patient
17 with low-grade astrocytoma, quantified as ++: a higher number of
cells are TSPO-positive; endothelial cells are also positive (arrows). c
Patient 19 with anaplastic astrocytoma, quantified as +++: an even
higher number of cells are TSPO-positive. Immunoperoxidase, ×20
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Performance of different reference tissue input functions
Previous [11C]-(R)PK11195 PET studies in various neurolog-
ical disorders and healthy ageing subjects employed SRTM
with either cerebellum or cluster analysis as the input function
[2, 10, 20–22, 52, 53]. Consequently, we also adopted these
previously used methods and assessed their performance in
our glioma and control cohorts. For the cerebellar input func-
tion, bilateral and not unilateral cerebellar GM was used in
gliomas for consistency with controls, and also because of its
larger volume and thus reduced noise.
Supervised clustering versus cerebellum input
Pixel-by-pixel comparisons of BPND parametric maps generat-
ed with supervised cluster analysis or cerebellar GM as a
reference tissue allowed us to compare the properties of these
two input functions in the absence of a plasma input function.
In control subjects, Bland-Altman plots and local regression,
together with comparisons of regional values, demonstrated no
systematic difference between the two approaches. Similar
findings were seen in 10 of 23 glioma patients. Such good
agreement indicates that these two reference input functions led
to consistent results in all the control subjects and approximate-
ly half of glioma patients.
However, in the other 13 of 23 patients, BPND values in
both the tumour and brain using the supervised cluster input
function were consistently smaller than those calculated
using the cerebellar input function. This observation indicates
either underestimation of BPND by the supervised cluster
input and/or overestimation by the cerebellar input, suggesting
that at least one of the approaches may be subject to bias.
Underestimation of BPND using the supervised cluster analysis
might be caused by (1) pixels in the tumour being mistakenly
included in the reference cluster, or (2) brain tissue outside the
tumour in patients differing from that in controls. An internal
mask derived from the PET data is used for clustering in the
supervised cluster approach with six classes [4], and although
low uptake areas in the tumour will be masked out, high uptake
foci might still be included in the reference cluster. Hence, the
first problem is indeed likely to occur in gliomas with high
[11C]-(R)PK11195 binding, especially those demonstrating
GM-like kinetics that are sufficiently similar to the kinetics in
the GM. In fact, focal or diffuse high [11C]-(R)PK11195 uptake
was observed in seven out of these 13 tumours, three of which
also showed GM-like kinetics. The inclusion of those tumour
pixels with high [11C]-(R)PK11195 signals in the reference
cluster will lead to underestimation of BPND. Regarding the
second problem, nonneoplastic cerebral regions might be af-
fected by intrahemispheric and transhemispheric diaschisis [54,
55], oedema or abnormal electroactivity induced by seizures,
any of which could trigger local or diffuse neuroinflammatory
responses and thus increased [11C]-(R)PK11195 uptake by
activated microglia [56–58]. It is possible that the supervised
clustering could be biased by such background changes and
extract abnormal pixels as reference. Indeed, visual inspection
of the GM class probability maps revealed that certain pixels
around the tumour margin or even within the tumour were
identified in some cases. Hence, a modified supervised cluster
analysis [26], with further supervision by masking out the
tumour pixels prior to clustering, would be likely to improve
the robustness of reference region extraction. To further study
all the aforementioned phenomena, absolute quantification
with plasma input function would be required.
On the other hand, overestimation of BPND using cerebellar
GM as an input function could occur due to ‘contamination’
by small volumes of cerebellar WM because of imperfect
segmentation or the partial volume effect. Although such
contamination altered the performance of cerebellar GM input
when compared with supervised cluster input, it should not
affect the use of cerebellar GM as a reference tissue, since
previous studies have adopted the total cerebellum as the input
function [2, 10, 20–22]. In the less common situation in which
a glioma localizes in the cerebellum (mainly paediatric cases;
beyond the scope of this study), the use of the unaffected
cerebellar hemisphere as the reference tissue might still be
preferred. Supervised cluster analysis extracts a cluster of GM
pixels from the whole brain including the cerebellum [4].
Therefore, it could possibly sample pixels with GM-like ki-
netics (if any) from a tumour located there. On balance, we
preferred the use of cerebellar GM input function because it
provided a conservative measure of [11C]-(R)PK11195 bind-
ing and the uptake differences between subject groups. This
implies that when a difference in binding is detected it is more
likely to represent a true positive result than differences dem-
onstrated by the supervised cluster approach.
Nevertheless, without the plasma input, we cannot give a
definitive answer as to which input function performed better,
nor can we guarantee that the cerebellar GM is absolutely spared
and does not contain increased specific binding (to activated
microglia) when compared with controls. Moreover, SRTM
suffers from bias in discrepancies in a blood volume fraction
between target and reference regions. This effect is further in-
creased by the presence of TSPO in blood vessel walls [19].
Taking into account the blood volume fraction, the vascular
corrected SRTM results in higher BPND estimates than the
SRTM [19]. Therefore, it may represent a better model for
glioma investigation, especially those with increased blood vol-
ume. This hypothesis will be investigated in our future work.
In addition, our imaging data showed that, despite certain
systematic differences in the BPND estimates in some sub-
jects depending on the input function used, the overall
anatomical pattern of significant [11C]-(R)PK11195 binding
did not alter in the same subject.
In conclusion, the three types of tracer kinetics in gliomas
are determined in part by the tracer delivery. They also
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reflect the heterogeneous nature of gliomas, and confirm
that [11C]-(R)PK11195 is a suitable radiotracer for glioma
imaging because of its unimpeded delivery to tumour tissue
and its well-characterized kinetics. Tracer kinetic analysis is
a valuable tool in the study of TSPO expression in gliomas
with potential for in vivo discrimination between low-grade
astrocytomas and low-grade oligodendrogliomas.
Supervised cluster input and cerebellar GM input produced
BPND estimates in good agreement with one another in
approximately half of the glioma patients, but showed con-
sistent discrepancies, albeit correlated BPND, in the other
half. However, the cerebellar input was preferred in our
study based on theoretical and practical considerations.
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